Oncologist. The. Symptom Management and Supportive Care
|
|
- Charla Parrish
- 5 years ago
- Views:
Transcription
1 The Oncologist Symptom Management and Supportive Care Prediction of the Responsiveness to Treatment with Erythropoiesis-Stimulating Factors: A Prospective Clinical Study in Patients with Solid Tumors TILMAN STEINMETZ, a MARTIN HELLMICH, b MICHAEL NEISE, c ALI ALDAUD, d CHRISTIAN LERCHENMÜLLER, e ANTONIS TSAMALOUKAS, f FRANCOISE FANDEL, a CHRISTOPH WEILIGMANN, e UWE TOTZKE, g STEPHAN SCHMITZ a Oncologic Outpatient Clinics in a Cologne, c Krefeld, d Leipzig, e Münster, and f Hilden, Germany; b Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany; g HPM Healthcare Project Management, Geneva, Switzerland Key Words. Anemia Erythropoietic proteins Predictive factors Corresponding receiver operating characteristic curve ABSTRACT Objective. Treatment with erythropoiesis-stimulating factors (ESFs) can ameliorate anemia associated with cancer and chemotherapy. However, half of anemic cancer patients do not respond even to high doses. To determine factors that are predictive of a treatment response, a multicenter, prospective study was performed. Patients and Methods. Investigated factors were baseline erythropoietin, reticulocytes and soluble transferrin receptor (stfr) after 2 weeks, and reticulocytes and hemoglobin after 4 weeks. Anemic patients with solid tumors received 150 g/week of darbepoetin concomitantly with chemotherapy. The dose was doubled if hemoglobin did not increase by >1 g/dl after 4 weeks. Patients were considered responders if hemoglobin increased by >2 g/dl or reached a level >12 g/dl within 8 12 weeks. Results. In total, 196 patients were enrolled; 61% of the intention-to-treat (ITT) and 68% of the per-protocol population were responders. In the ITT population, the hemoglobin increase after 4 weeks indicated an 11-fold higher chance of response (odds ratio, 11.0; 95% confidence interval [CI], ; sensitivity, 88%; specificity, 60%). In a multiple logistic regression model including all factors, the area under the receiver operating characteristic curve was 0.78 (95% CI, ). The combination of stfr after 2 weeks and hemoglobin after 4 weeks was as predictive as the combination of all five tested factors. Conclusion. So far, an early hemoglobin increase remains the single most predictive factor for response to ESF treatment. In contrast to anemic patients with lymphoproliferative malignancies, serum erythropoietin had little predictive value in patients with solid tumors. The Oncologist 2007;12: Disclosure of potential conflicts of interest is found at the end of this article. INTRODUCTION Malignant diseases along with chemotherapy often result in anemia [1, 2]. The most important symptom associated with anemia is fatigue [3], which affects 75% of patients and prevents over 90% of them from maintaining a normal life [4]. Moreover, low hemoglobin (Hb) levels have a negative im- Correspondence: H. Tilman Steinmetz, M.D., Praxis für Hämatologie und Onkologie, Sachsenring 69, Cologne, Germany. Telephone: ; Fax: ; steinmetz@oncokoeln.de Received January 29, 2007; accepted for publication March 29, AlphaMed Press /2007/$30.00/0 doi: /theoncologist The Oncologist 2007;12:
2 Steinmetz, Hellmich, Neise et al. 749 pact on cancer prognosis and therapy outcome [5 9]. In order to improve quality of life and prognosis, the treatment and prevention of anemia is now considered an integral part of the management of malignant diseases. Treatment with transfusions is inconvenient for the patient, acts transiently and insufficiently at peripheral tissues, and is associated with increased risks for infections and adverse immune reactions, which also worsen the prognosis [10, 11]. Erythropoiesis-stimulating factors (ESFs), such as hyperglycosylated darbepoetin alfa (DA), constitute an alternative treatment with proven efficacy and without most of the disadvantages associated with transfusions. However, treatment with ESFs is expensive and, unlike in end-stage renal disease, response rates in cancer amount to only 50% 70%, although they tend to increase with treatment duration [12]. Among the factors known to influence the responsiveness to ESF treatment are the type and state of the underlying malignant disease, the existence of other potential causes of anemia (e.g., hemorrhage), functional iron deficiency, and the type and dose of chemotherapy. Baseline levels of Hb, hematocrit, and endogenous erythropoietin (EPO), as well as increases in Hb, reticulocytes, and soluble transferrin receptor (stfr) during the initial treatment phase with ESF, have been evaluated as predictive factors for treatment response in several studies [13 18]. However, no study has revealed any baseline predictive factor that can be routinely used in clinical practice [19] and only a few small clinical trials have validated predictive factors prospectively [20 22]. A recent Cochrane review [23] concluded that virtually all studies to date assessing predictive factors of response to EPO were small, exploratory in nature, and of low reporting quality. The review stated that the current evidence did not allow for definite conclusions to be made and called for larger, high-quality prospective studies. In line with these recommendations, the current multicenter, prospective study was performed in ambulatory patients with solid tumors who had been attending a regular medical practice. MATERIALS AND METHODS Study Design This was a 12-week prospective trial in outpatients receiving commonly used chemotherapy allowing one dose escalation after 4 weeks. It was approved by the corresponding ethics committee and conducted in accordance with the declaration of Helsinki, good clinical practices, and legal obligations (AMG). All participants gave written informed consent prior to participation. Figure 1. Study populations. Abbreviations: ITT, intention to treat; PP, per protocol; stfr, soluble transferrin receptor. Patients and Treatment Eligible patients had to have an Eastern Cooperative Oncology Group performance status score 2 and anemia (defined as either a total Hb 11g/dl or a Hb decrease 1.5 g/dl over 4 weeks). Patients received DA s.c. for 12 weeks concomitantly with chemotherapy at doses of either 150 g/week or 300 g every other week. The dosage was adjusted to 300 g/week if Hb did not increase by 1 g/dl by week 4. DA treatment was prematurely discontinued when Hb exceeded 14 g/dl in responders or discontinued for no response if the level changed by 1 g/dl after week 8. DA (Aranesp ; Amgen Inc., Thousand Oaks, CA) is an analogue of recombinant human erythropoietin (rhuepo). Its higher number of sialic acid moieties compared with rhuepo results in lower affinity for the erythropoietin receptor but a longer half-life that ultimately makes DA more potent in vivo than rhuepo. Administration can be less frequent and thus more easily synchronized with chemotherapy. In randomized, controlled clinical trials, s.c. DA given at appropriate doses once every 1 3 weeks has been shown to be an effective and well-tolerated erythropoietic agent in anemic cancer patients undergoing chemotherapy [24 27]. Response Criteria Response was defined as an increase in Hb of 2 g/dl from baseline or as a total level of 12 g/dl to be achieved within
3 750 Prediction of Responsiveness to ESF Treatment Table 1. Baseline characteristics of the intention-to-treat population Characteristic Total Nonresponder Responder Age (years) a Weight (kg) a d 14.4 Height (cm) a Sex b Male Female Performance status b according to WHO/ECOG Hematocrit (%) c Erythrocytes (10 12 /l) c Reticulocytes ( ) c Leukocytes (10 9 /l) c Platelets (10 9 /l) c a Mean and standard deviation. Percentage and number of patients. Median, percentiles. d Responders versus nonresponders, Wilcoxon rank sum test p.006. Abbreviations: ECOG, Eastern Cooperative Oncology Group; WHO, World Health Organization. Table 2. Requirement for concomitant anemia therapy or DA dose escalation ( 150 g DA at week 4) Total Nonresponder Responder Intervention % n % n % n Iron therapy No Yes Transfusion therapy No Yes a 9 Dose escalation No Yes b 29 a Responders versus nonresponders, 2 test, p b p Abbreviation: DA, darbepoetin alfa weeks. For patients who were transfused during the first month of the study, the Hb level determined immediately afterward was taken as baseline. Patients who received a transfusion between week 5 and week 8 were considered nonresponders. The following prespecified criteria were investigated for their predictive value of the treatment response: (a) serum EPO 100 U/l at baseline or the ratio of the observed (0.093 hematocrit [%]) to predicted level (O/P) (P 10 [28]) 0.9 at baseline, (b) reticulocytes 40,000/ l after 2 weeks, (3) an increase in stfr 25% after 2 weeks, (d) reticulocytes 40,000/ l after 4 weeks, and (e) an increase in Hb 1 g/dl after 4 weeks. Blood samples were taken every other week and analyzed at the local sites for EPO, Hb, reticulocytes, and stfr. At baseline, vital signs and safety laboratory parameters were also measured.
4 Steinmetz, Hellmich, Neise et al. 751 Table 3. Predictive value (OR), positive/negative LR, and corresponding 95% CI of the five predictive factors (EPO at baseline, reticulocytes and stfr increase after 2 weeks, and reticulocytes and Hb increase after 4 weeks) in the ITT population Factor Day OR (95% CI) LR (95% CI) LR (95% CI) EPO, O/P ratio ( ) 1.1 ( ) 0.6 ( ) EPO 100 U/l ( ) 1.1 ( ) 0.6 ( ) Reticulocytes 40,000/ l ( ) 1.6 ( ) 0.9 ( ) stfr increase 25% ( ) 1.4 ( ) 0.5 ( ) Reticulocytes 40,000/ l ( ) 2.4 ( ) 0.9 ( ) Hb increase 1g/dl ( ) 4.8 ( ) 0.4 ( ) LR values 5 and LR values 0.2 indicate strong diagnostic evidence. Abbreviations: CI, confidence interval; EPO, erythropoietin; Hb, hemoglobin; ITT, intention-to-treat; LR, likelihood ratio; O/P, observed to predicted level; OR, odds ratio; stfr, soluble transferrin receptor. Data Sets Patients who fulfilled all inclusion and none of the exclusion criteria and for whom the response to DA could be evaluated entered the intention-to-treat (ITT) population. All patients without any protocol violation and for whom all scheduled predictive factors were recorded comprised the per-protocol data set (Fig. 1). Statistical Analysis The predictive value of each factor was evaluated by calculating odds ratios (ORs) and likelihood ratios (LRs). In addition, combinations of factors were evaluated based on multiple logistic regression models and corresponding receiver operating characteristic (ROC) curves. The ROC curve depicts the trade-off between sensitivity and 1 specificity for various cutoffs used to classify patients as either a responder or nonresponder. The discriminatory power of a combination of factors is usually summarized by the area under the ROC curve (AUC) (1, perfect discrimination; 0.5, tossing a coin, which corresponds to the random ROC ). Differences between nested models were tested by LR tests. The calibration of models, that is, the agreement of observed and predicted proportions of response, was assessed by the Hosmer Lemeshow statistic. The association between the Hb increase within 8 12 weeks and that after 4 weeks of DA treatment was analyzed by ordinary least-squares regression, 80% prediction limits, and Pearson s correlation coefficient. The sample size required to obtain a reliable classification rule was calculated based on the rule of thumb 10 events per variable of interest [29] and an expected 40% proportion of nonresponders. To account for dropouts and missing values, a total sample size of 200 was targeted. Statistical analyses were performed with SPSS (SPSS Inc., Chicago, IL) and R (R Foundation for Statistical Computing, Vienna, Austria). Figure 2. ROC curves based on ITT data and multiple logistic regression models. (A): Includes all five factors (AUC, 0.78; 95% CI, ). (B): Includes the three factors available after 2 weeks (AUC, 0.63; 95% CI, ). (C): Includes only baseline EPO (AUC, 0.54; 95% CI, ). Abbreviations: AUC, area under the curve; CI, confidence interval; EPO, erythropoietin; ITT, intention to treat; ROC, receiver operating characteristic curve. RESULTS In total, 299 patients were screened; 196 of them, 112 women and 84 men with a mean age of 64 years, were enrolled, treated, and evaluated for their response to DA (Fig. 1). About 61% of the ITT and 68% of the PP population were responders (online supplementary Figure 1). Apart from body weight, responders and nonresponders did not differ significantly in demographics (Table 1), vital signs
5 752 Prediction of Responsiveness to ESF Treatment Table 4. Multiple logistic regression models with one (baseline), three (after 2 weeks of DA treatment), or five factors (after 4 weeks of DA treatment), or two selected factors, based on the ITT population Day B SE (B) Wald test OR Hosmer Lemeshow test LR test p-value Exp (B) 95% CI 2 LL df p-value Statistic df p-value Constant EPO 100 U/l Constant EPO 100 U/l Reticulocytes 40,000/ l stfr increase 25% Constant EPO 100 U/l Reticulocytes 40,000/ l stfr increase 25% Reticulocytes 40,000/ l Hb increase 1 g/dl Constant stfr increase 25% Hb increase 1 g/dl Constant Abbreviations: B, coefficient; CI, confidence interval; DA, darbepoetin alfa; df, degrees of freedom; EPO, erythropoietin; Hb, hemoglobin; ITT, intention to treat; OR, odds ratio; LL, log likelihood; LR, likelihood ratio; SE, standard error; stfr, soluble transferrin receptor.
6 Steinmetz, Hellmich, Neise et al. 753 (data not shown), or laboratory data at baseline (Table 1) (clinical chemistry data not shown). Nonresponders required significantly more frequent transfusions and DA dose escalation (p.001; Table 2). Patients who displayed an increase in Hb after 4 weeks had an 11-fold higher chance of being responders than those who did not. Taken alone, all other investigated factors had rather low predictive values without clinical relevance (Table 3). ROC curves corresponding to multiple logistic regression models including all five factors revealed an AUC of 0.78 (95% confidence interval [CI], ) (Fig. 2) in the ITT population and 0.83 (95% CI, ; data not shown) in the PP population. Blockwise removal of factors, first of those evaluated after 4 weeks and then of those evaluated after 2 weeks, consistently decreased the predictive value of the model (Fig. 2 and Table 4). Following the opposite approach, removal of baseline EPO and of reticulocytes (determined after 2 or 4 weeks) from the model had no impact (AUC, 0.78; 95% CI, ; Table 4). Calibration of all logistic models appeared to be good (Hosmer Lemeshow statistic 2). Multiple linear regression models of the Hb increase within 8 12 weeks with any of the tested factors were not significant, except for the Hb increase measured after 4 weeks (Fig. 3). DISCUSSION This study is the first to prospectively evaluate predictive factors for the responsiveness of ambulatory cancer patients to ESF treatment based on regular medical practice conditions. These conditions were important because the study aimed to provide a valid and readily usable instrument for treatment decisions in oncologists day-to-day practice. In a conservative approach, transfused patients were included in the analysis. Given this, the study revealed relatively high response rates but, like all former studies [23], failed to find a single predictive factor or combinations of factors that would allow a reliable response prediction prior to or during early treatment. However, it did provide: (a) for the first time, a statistical model with Hb and stfr as predominant factors aiding oncologists day-to-day decision of whether or not to continue ESF therapy at least after 4 weeks of treatment, and (b) some new insights into hematopoiesis that may also affect routine practice. In contrast to anemic patients with lymphoproliferative malignancies [17, 30, 31], neither the baseline EPO level nor the O/P ratio predicted response to DA in anemic patients with solid tumors. This confirms isolated observations from retrospective analyses [16, 30]; however, there is no conclusive explanation for such a difference and there is a need for confirmation in further prospective trials enrolling and directly comparing both types Figure 3. Linear regression of the Hb increase within weeks 8 12 with the one measured after 4 weeks of DA treatment (broken lines reflect 80% prediction limits). Patients transfused after 4 weeks were considered nonresponders. Abbreviations: DA, darbepoetin alfa; Hb, hemoglobin. of patients. Contrary to previous studies [14, 18], reticulocytes also had little relevance for response prediction, which might be related to the simultaneous chemotherapy, because this was also observed in another trial with patients who were treated concomitantly [32]. The slightly higher predictive value of the stfr increase was, however, in line with former studies [14] and could be expected, because it is thought to correlate with an increase in the mass of erythropoietic precursors within the bone marrow. The factor with the highest predictive value was the Hb increase after 4 weeks of treatment. Increases in Hb are generally easy to measure and have also been established as the main predictive factor by former studies [13, 18, 22, 32]. A least-squares regression of the Hb increase within 8 12 weeks with that measured after 4 weeks of DA treatment yielded a simple prediction rule that might be helpful in clinical practice, that is, Hb week 8 12 [g/dl] 0.7 Hb week ( 2 for 80% of cases) (Fig. 3). However, the value of such models generally remains uncertain in practice. If after 4 weeks of ESF treatment the probability of an increase in Hb is low, should therapy then be stopped? What level of certainty would be needed to continue? To answer these kinds of questions it must be taken into account that hemoglobin is just a surrogate marker for the real objectives of ESF therapy: (a) the improvement of quality of life and (b) the prevention of transfusions. However, neither of these has yet been built into models predicting ESF treatment response. Thus, further
7 754 Prediction of Responsiveness to ESF Treatment studies are needed to identify factors that allow for the assessment of the efficacy of ESF therapy prior to or during early treatment in order to prevent side effects, reduce costs, and improve quality of life. ACKNOWLEDGMENTS The study was supported by Amgen GmbH, Germany, and was presented as abstract at the American Society of Clinical Oncology 2006 Annual Meeting. DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST T.S. has acted as a consultant for Amgen, Hoffmann-La Roche, and Ortho Biotech. C.L. has acted as a consultant for Amgen. REFERENCES 1 Khayat D. Is anemia a problem for European cancer patients and treating oncologists? Semin Oncol 2000;27(suppl 4):9 11; discussion Barrett-Lee PJ, Bailey NP, O Brien ME et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000;82: Ashbury FD, Findlay H, Reynolds B et al. A Canadian survey of cancer patients experiences: Are their needs being met? J Pain Symptom Manage 1998;16: Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT- An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(suppl 2): Fein DA, Lee WR, Hanlon AL et al. Pretreatment hemoglobin level influences local control and survival of T1 T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995;13: Dubray B, Mosseri V, Brunin F et al. Anemia is associated with lower localregional control and survival after radiation therapy for head and neck cancer: A prospective study. Radiology 1996;201: Waters JS, O Brien ME, Ashley S. Management of anemia in patients receiving chemotherapy. J Clin Oncol 2002;20: Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebocontrolled trial. J Clin Oncol 2001;19: Glaser CM, Millesi W, Kornek GV et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50: Heiss MM, Mempel W, Delanoff C et al. Blood transfusion-modulated tumor recurrence: First results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994;12: Jensen LS, Kissmeyer-Nielsen P, Wolff B et al. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996;348: Malik IA, Khan ZK, Hakimali A et al. The effect of subcutaneous recombinant human erythropoietin (r-huepo) on anemia in cancer patients receiving platinum-based chemotherapy. J Pak Med Assoc 1998;48: Goram AL. Factors and predictors of response with epoetin alfa for chemotherapy-related anemia. J Pharm Technol 2000;16: Cazzola M, Ponchio L, Pedrotti C et al. Prediction of response to recombinant human erythropoietin (rhuepo) in anemia of malignancy. Haematologica 1996;81: Littlewood TJ, Zagari M, Pallister P. Pretreatment erythropoietin levels cannot be used to predict individual response to epoetin alfa in anaemic cancer patients. Curr Med Res Opin 2005;21(suppl 2):S19 S Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40: Kolesar JM, Duren BA, Baranski BG. Retrospective evaluation of response to epoetin alfa in patients with hematologic disorders. J Oncol Pharm Pract 2004;10: Littlewood TJ, Zagari M, Pallister C et al. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. The Oncologist 2003;8: Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43: Katodritou E, Speletas M, Kapetanos D et al. Evaluation of traditional and novel predictive markers of anemia response to recombinant human erythropoietin (rh-epo) in patients with multiple myeloma and lymphoma: Emerging role of functional iron deficiency. Blood 2004;104:8B. 21 Katodritou E, Speletas M, Zervas K et al. Evaluation of hypochromic erythrocytes in combination with stfr-f index for predicting response to r- HuEPO in anemic patients with multiple myeloma. Lab Hematol 2006;12: Gonzalez-Baron M, Ordonez A, Franquesa R et al. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy. Cancer 2002;95: Trelle S, Piper M, Bohlius J et al. Predictive factors of response to recombinant human erythropoietin: Quality and results of studies identified by a systematic review. Onkologie 2006;29(suppl 3): Canon JL, Vansteenkiste J, Bodoky G et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98: Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94: Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: Glaspy J, Henry D, Patel R et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41: Beguin Y, Yerna M, Loo M et al. Erythropoiesis in multiple myeloma: Defective red cell production due to inappropriate erythropoietin production. Br J Haematol 1992;82:
8 Steinmetz, Hellmich, Neise et al Harrell F Jr. Regression Modeling Strategies. New York: Springer, 2001: Cheer SM, Wagstaff AJ. Epoetin beta: A review of its clinical use in the treatment of anaemia in patients with cancer. Drugs 2004;64: Cazzola M, Beguin Y, Kloczko J et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003; 122: Lastiri JM, Specterman SR, Rendo P et al. [Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer.] Medicina (B Aires) 2002;62:
The. JOHN GLASPY, a,e LAURENT DEGOS, b,e MARIO DICATO, c,e GEORGE D. DEMETRI d,e LEARNING OBJECTIVES ABSTRACT
The Oncologist Comparable Efficacy of Epoetin Alfa for Anemic Cancer Patients Receiving Platinum- and Nonplatinum-Based Chemotherapy: A Retrospective Subanalysis of Two Large, Community-Based Trials JOHN
More informationOncologist. The. Symptom Management and Supportive Care
The Oncologist Symptom Management and Supportive Care The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Hematologic Outcomes and Quality of Life in Older Patients With Chemotherapy-Induced
More informationJune 12, Dear Dr. Phurrough:
June 12, 2007 Steve E. Phurrough, MD, MPA Director, Coverage and Analysis Group Centers for Medicare & Medicaid Services Mail Stop C1-09-06 7500 Security Boulevard Baltimore, MD 21244 Dear Dr. Phurrough:
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationABSTRACT. Keywords: Chemotherapy induced anaemia, gastrointestinal cancers, India.
An Open Labeled Two Arm Study to Evaluate the Feasibility, Quality of Life, Safety and Efficacy of Darbepoetin as Compared to Erythropoietin Inpatients with Chemotherapy Induced Anemia in Patients with
More informationProduct: Darbepoetin alfa Clinical Study Report: Date: 22 August 2007 Page 2 of 14145
Date: 22 ugust 2007 Page 2 of 14145 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C, US Name of Finished Product: ranesp Name of ctive Ingredient: Darbepoetin alfa Title of Study: Randomized,
More informationPREDICTION OF RESPONSE TO OPTIMIZE OUTCOME OF TREATMENT WITH ERYTHROPOIETIN. Yves Beguin
PREDICTION OF RESPONSE TO OPTIMIZE OUTCOME OF TREATMENT WITH ERYTHROPOIETIN Yves Beguin Senior Research Associate of the National Fund for Scientific Research (FNRS, Belgium). Department of Medicine, Division
More informationEffective Health Care
Number 3 Effective Health Care Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Executive Summary Background Anemia (deficiency of red blood
More informationErythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in
Erythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in thoracic tumors and MICU Dr Dipesh Maskey Senior Resident Dept of Pulmonary & CCM 14 th Oct 2011 Anemia and cancer
More informationApril 12, Coverage of ESAs for Patients with Conditions Other than End-Stage Renal Disease
[ASH Comments to the Centers for Medicare and Medicaid Services on coverage for Erythropoiesis Stimulating Agents (ESAs) filed electronically on April 12, 2007] April 12, 2007 The American Society of Hematology
More informationDarbepoetin alpha in the treatment of cancer chemotherapy-induced anemia
REVIEWS Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia Alberto Grossi 1 Francesca Balestri 2 Simone Santini 3 1 IstitutoLeonardo da Vinci Hematology, Florence, Italy; 2 Blood
More informationAnaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
More informationResponse Predicting Factors to Recombinant Human Erythropoietin in Cancer Patients Undergoing Platinum-Based Chemotherapy
2408 Response Predicting Factors to Recombinant Human Erythropoietin in Cancer Patients Undergoing Platinum-Based Chemotherapy Manolo González-Barón 1 Amdio Ordóñez 1 Rosa Franquesa 2 Manuel Constenla
More informationSafety Update on Erythropoiesis-Stimulating Agents: Trials Within and Outside the Accepted Indications
Safety Update on Erythropoiesis-Stimulating Agents: Trials Within and Outside the Accepted Indications Pere Gascón Medical Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
More informationManaging Anemia in the Cancer Patient: Old Problems, Future Solutions Michael S. Gordon. doi: /theoncologist
Managing Anemia in the Cancer Patient: Old Problems, Future Solutions Michael S. Gordon The Oncologist 2002, 7:331-341. doi: 10.1634/theoncologist.7-4-331 The online version of this article, along with
More informationErythropoiesis Stimulating Agents (ESA)
Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription
More informationSymptom Management and Supportive Care
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Symptom Management and Supportive Care Early Intervention with
More informationOncologist. The. Symptom Management and Supportive Care
The Oncologist Symptom Management and Supportive Care A Randomized, Open-Label, Multicenter Trial of Immediate Versus Delayed Intervention with Darbepoetin Alfa for Chemotherapy-Induced Anemia VEENA CHARU,
More informationA New Dose-intense Epoetin Alfa Regimen Effective in Anemic Cancer Patients Receiving Chemotherapy: An Open-label, Non Randomized, Pilot Study
A New Dose-intense Epoetin Alfa Regimen Effective in Anemic Cancer Patients Receiving Chemotherapy: An Open-label, Non Randomized, Pilot Study DANIELE SANTINI 1, BRUNO VINCENZI 1, ANNALISA LA CESA 1, VLADIMIR
More informationIron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia
Iron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia Paolo Pedrazzoli, MD 1, Giovanni Rosti, MD 2, Simona Secondino, MD 1, and Salvatore Siena, MD 1 Unresponsiveness
More informationMHRA Public Assessment Report. Epoetins for the management of anaemia associated with cancer: risk of tumour progression and mortality.
MHRA Public Assessment Report Epoetins for the management of anaemia associated with cancer: risk of tumour progression and mortality November 2007 Executive summary 2 Introduction 5 Epoetins for treatment
More informationClinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia
Clinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia 8 th November 2004 A report for the National Institute for Clinical Excellence prepared by Amgen Ltd. EXECUTIVE SUMMARY
More informationBC Cancer Protocol Summary Guidelines for the Use of Erythropoiesis-Stimulating Agents (ESAs) in Patients with Cancer
BC Cancer Protocol Summary Guidelines for the Use of Erythropoiesis-Stimulating Agents (ESAs) in Patients with Cancer Protocol Code SCESA Tumour Group Physician Contact Pharmacist Contact Supportive Care
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationRadiotherapy-Associated Anemia: The Scope of the Problem
Radiotherapy-Associated Anemia: The Scope of the Problem LOUIS B. HARRISON, DANIEL SHASHA, CAROL WHITE, BEVERLY RAMDEEN Department of Radiation Oncology, Beth Israel Medical Center, St. Luke s-roosevelt
More informationFrequency of ABO Blood Group and Decreased Level of Hemoglobin in Lung Cancer Patients
Year: 2014; Volume: 1; Issue: 1 Article ID: CR14 02; Pages: 1-6 Advances in Cancer Research & Therapy Research Article Frequency of ABO Blood Group and Decreased Level of Hemoglobin in Lung Cancer Patients
More informationCentocor Ortho Biotech Services, LLC
SYNOPSIS Issue Date: 17 June 2009 Name of Sponsor/Company Name of Finished Product PROCRIT Name of Active Ingredient(s) Protocol No.: PR04-15-001 Centocor Ortho Biotech Services, LLC Epoetin alfa Title
More informationResearch Article Wiley Periodicals, Inc.
Research Article Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: A prospective multicenter randomized trial Yves Beguin, 1,2 * Johan Maertens,
More informationAnemia is a common occurrence in cancer patients, resulting from
1072 Once-Weekly Dosing of Epoetin- Increases Hemoglobin and Improves Quality of Life in Anemic Cancer Patients Receiving Radiation Therapy Either Concomitantly or Sequentially with Chemotherapy Daniel
More informationAnemia of Chronic Disease
J KMA Special Issue Anemia of Chronic Disease Chul Soo Kim, MD Department of Internal Medicine, Inha University College of Medicine Email : cskimmd@inha.ac.kr J Korean Med Assoc 2006; 49(10): 920-6 Abstract
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationAETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)
AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationErythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis
Original Article Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis Xiaomei Li 1,2, Zhi Yan 3, Dexiao Kong 2,4, Wen Zou 5, Jihua Wang 1, Dianshui Sun 1,
More informationVenous Thromboembolic Events and Erythropoiesis-Stimulating Agents: An Update
Venous Thromboembolic Events and Erythropoiesis-Stimulating Agents: An Update Mario Dicato Hematology-Oncology Service, Luxembourg Medical Centre, Luxembourg Key Words. Erythropoiesis-stimulating agents
More informationErythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
BENEFITS AND RISKS OF ESAs IN CANCER MEDICAL ONCOLOGY Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer B.L. Melosky MD ABSTRACT Anemia, already common in cancer patients,
More informationKey Words. Anemia Cancer Chemotherapy Economic Erythropoiesis-stimulating agents Transfusion
The Oncologist Symptom Management and Supportive Care Health Economic Evaluation of Treating Anemia in Cancer Patients Receiving Chemotherapy: A Study in Belgian Hospitals ERIK SPAEPEN, a NADIA DEMARTEAU,
More informationMedication Prior Authorization Form
Procrit, Aranesp and (Epoetin Alfa) Policy Number: 1043 Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not
More informationLiterature Scan: Erythropoiesis Stimulating Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDrug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs)
Drug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs) Line of Business: Medicaid P & T Approval Date: May 16, 2018 Effective Date: July 1, 2018 This policy has been developed
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationDarbepoetin alfa administration in patients with non-hodgkin lymphoma and chemotherapy-induced anemia receiving (±R)CHOP
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2013 Darbepoetin alfa administration in patients with non-hodgkin lymphoma
More informationComparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care Hospital
Human Journals Research Article July 2017 Vol.:9, Issue: 4 All rights are reserved by Pournami A S et al. Comparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care
More informationClinical Policy: Darbepoetin alfa (Aranesp) Reference Number: ERX.SPMN.13
Clinical Policy: (Aranesp) Reference Number: ERX.SPMN.13 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationDose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
Adv Ther (2013) 30:1007 1017 DOI 10.1007/s25-013-0063-y ORIGINAL RESEARCH Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study Peter Choi Mourad
More informationdoi: /theoncologist
Treating Anemia of Cancer with Every-4-Week Darbepoetin Alfa: Final Efficacy and Safety Results from a Phase II, Randomized, Double-Blind, Placebo-Controlled Study David Gordon, Gwen Nichols, Ali Ben-Jacob,
More informationSensitivity, specicity, ROC
Sensitivity, specicity, ROC Thomas Alexander Gerds Department of Biostatistics, University of Copenhagen 1 / 53 Epilog: disease prevalence The prevalence is the proportion of cases in the population today.
More informationMiriam Kimel, PhD, Nancy K. Leidy, PhD, Sally Mannix, BA, Julia Dixon, BS
Volume 11 Number 1 2008 VALUE IN HEALTH Does Epoetin Alfa Improve Health-Related Quality of Life in Chronically Ill Patients with Anemia? Summary of Trials of Cancer, HIV/AIDS, and Chronic Kidney Disease
More informationCorporate Medical Policy Erythropoiesis-Stimulating Agents (ESAs)
Corporate Medical Policy Erythropoiesis-Stimulating Agents (ESAs) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: erythropoiesis_stimulating_agents_(esas) 8/2011 3/2018 3/2019 6/2018
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES PROCRIT METHOXY PEG-EPOETIN BETA MIRCERA 35005
Generic Brand HICL GCN Exception/Other DARBEPOETIN ALFA IN ARANESP 22890 POLYSORBATE EPOETIN ALFA EPOGEN, 04553 PROCRIT METHOXY PEG-EPOETIN BETA MIRCERA 35005 GUIDELINES FOR USE NOTE: Requirements regarding
More informationCurrent situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin theta, 1,000 IU/0.5mL, 2,000 IU/0.5mL, 3,000 IU/0.5mL, 4,000 IU/0.5mL, 5,000 IU/0.5mL, 10,000 IU/1mL, 20,000 IU/1mL, 30,000 IU/1mL solution for injection in pre filled
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Darbepoetin Alfa (Aranesp) Reference Number: CP.PHAR.236 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important
More informationANEMIA IN CANCER ROLE OF IV IRON
ANEMIA IN CANCER ROLE OF IV IRON IRON DEFICIENCY Absolute vs functional Absolute iron deficiency µ anemia = no iron stores : ferritin < 20 µg/l in N individual < 100 µg/l in infl/cancer patient Functional
More informationAnemia Management: Using Epo and Iron
Anemia Management: Using Epo and Iron Ky Stoltzfus, MD University of Kansas Medical Center Assistant Professor Department of Internal Medicine January 23, 2013 Regulation of red cell production Treatment
More informationWhat are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L
What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L Record Status This is a critical abstract of an economic evaluation
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Methoxy polyethylene glycol (PEG) epoetin-beta (Mircera ) Non-Discrimination Statement and Multi-Language
More informationChronic anemia is a common complication of
Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients Trends in Hematology/Oncology review haematologica 2002; 87:1209-1221
More informationUtilizing Sysmex RET He to Evaluate Anemia in Cancer Patients
Utilizing Sysmex RET He to Evaluate Anemia in Cancer Patients Ellinor I. Peerschke, Ph.D., F.A.H.A. Vice Chair, Laboratory Medicine Chief, Hematology & Coagulation Laboratory Services Memorial Sloan Kettering
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationControversies in Transfusion Medicine
Controversies in Transfusion Medicine Jeffrey L. Carson, M.D. Richard C. Reynolds Professor of Medicine Chief, Division of General Internal Medicine Robert Wood Johnson Medical School New Brunswick, New
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationFDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ES...
Page 1 of 5 Home> Drugs> Drug Safety and Availability> Postmarket Drug Safety Information for Patients and Providers Drugs FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit,
More informationOutcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
Support Care Cancer (2012) 20:159 165 DOI 10.1007/s00520-010-1083-7 ORIGINAL ARTICLE Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia Chris L. Pashos &
More informationCost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
FORMULARY MANAGEMENT Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia PIERRE Y. CRÉMIEUX, PhD; JOHN M. FASTENAU, RPh, MPH; GEORGE KOSICKI, PhD;
More informationEffective Health Care Program
Comparative Effectiveness Review Number 83 Effective Health Care Program Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease Executive Summary Background Chronic
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Bohlius J, Schmidlin K, Brillant C, et
More informationCPR 3.5. EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED HB
CPR 3.5. EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED HB Although relative resistance to the effect of ESAs is a common problem in managing the anemia of patients with CKD
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationMeta analysis in Drug Safety Assessment with a Focus on ESA s and Diabetes
Meta analysis in Drug Safety Assessment with a Focus on ESA s and Diabetes Jesse A. Berlin, ScD Johnson & Johnson Pharmaceutical Research and Development Seattle Clinical Trials Symposium 22 November 2010
More informationErythropoetin (alpha and beta) and darbepoetin for the treatment of cancertreatment
National Institute for Health and Clinical Excellence Erythropoetin (alpha and beta) and darbepoetin for the treatment of cancertreatment induced anaemia Royal College of Nursing Introduction With a membership
More informationPharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report
British Journal of Cancer (2001) 84 (Supplement 1), 11 16 doi: 10.1054/ bjoc.2001.1747, available online at http://www.idealibrary.com on Pharmacokinetics of novel erythropoiesis stimulating protein (NESP)
More informationIron deficiency in gastrointestinal oncology
INVITED REVIEW Annals of Gastroenterology (2014) 27, 1-6 Iron deficiency in gastrointestinal oncology Kristof Verraes, Hans Prenen University Hospitals Leuven, Belgium Abstract Anemia is a very common
More informationA Mechanism-Based PK/PD Model Predicts the Time-Course of Hematological responses for Epoetin beta
A Mechanism-Based PK/PD Model Predicts the Time-Course of Hematological responses for Epoetin beta N. Hayashi, K. P. Zuideveld, P. Jordan & R. Gieschke Modeling & Simulation Group & Biometrics, F. Hoffmann-La
More informationPractice and Costs of Red Blood Cell (RBC) Transfusion in an Oncological Unit
Practice and Costs of Red Blood Cell (RBC) Transfusion in an Oncological Unit JAN NORUM 1,2 and MARI-ANN N. MOEN 3 1 Department of Oncology, University Hospital of North Norway, Tromsø; 2 Institute of
More informationErythropoiesis-Stimulating Agents
Erythropoiesis-Stimulating Agents Policy Number: 5.01.04 Last Review: 8/2017 Origination: 8/2015 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationOriginal article. chemotherapy ranges from 9% to 40% [3]. Anemia related to platinum-containing chemotherapy
Annals of Oncology 9: 255-260. 1998. 1998 Kluwer Academic Publishers. Primed in the Netherlands. Original article Recombinant human erythropoietin in the treatment of chemotherapyinduced anemia and prevention
More informationRecombinant human erythropoietin in cancer-treatment related anaemia.
Recombinant human erythropoietin in cancer-treatment related anaemia. A submission to the NICE technology appraisal process on behalf of the Royal College of Physicians, Royal College of Radiologists,
More informationDrugs Used in Anemia
Drugs Used in Anemia Drugs of Anemia Anemia is defined as a below-normal plasma hemoglobin concentration resulting from: a decreased number of circulating red blood cells or an abnormally low total hemoglobin
More informationRecombinant human erythropoietin (epoetin alfa) has been used in clinical settings for
REVIEW ARTICLE Epoetin Alfa Clinical Evolution of a Pleiotropic Cytokine David H. Henry, MD; Peter Bowers, MD; Michael T. Romano, PhD; Robert Provenzano, MD Recombinant human erythropoietin (epoetin alfa)
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationAs cancer shifts from an inevitable death
CHEMOTHERAPY-INDUCED ANEMIA: TREATING IT AS A DISEASE, NOT JUST A CONDITION J. Michael Hayes, PharmD, RPh * ABSTRACT Anemia related to cancer treatment has multiple etiologies, including bleeding, marrow
More informationErythropoiesis-Stimulating Agents (ESA s): epoetin alfa (Epogen and Procrit ), darbepoetin alfa (Aranesp ), and pegylated epoetin beta (Mircera )
Erythropoiesis-Stimulating Agents (ESA s): epoetin alfa (Epogen and Procrit ), darbepoetin alfa (Aranesp ), and pegylated epoetin beta (Mircera ) Applies to all products administered or underwritten by
More informationErythropoiesis-Stimulating Agents (ESA s): Epoetin (Epogen and Procrit ), and Darbepoetin (Aranesp )
Erythropoiesis-Stimulating Agents (ESA s): Epoetin (Epogen and Procrit ), and Darbepoetin (Aranesp ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationAnaemia is a shortage of red blood cells and haemoglobin. If you have anaemia, doctors say that you are anaemic.
Freephone helpline 0808 808 5555 information@lymphoma-action.org.uk www.lymphoma-action.org.uk Anaemia Anaemia means that there is too little haemoglobin (the chemical that carries oxygen) and too few
More informationClinical Policy Title: Erythropoietin for end-stage renal disease
Clinical Policy Title: Erythropoietin for end-stage renal disease Clinical Policy Number: 00.02.07 Effective Date: June 1, 2015 Initial Review Date: February 19, 2014 Most Recent Review Date: January 18,
More informationARANESP (darbepoetin alfa) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2001
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARANESP safely and effectively. See full prescribing information for ARANESP. ARANESP (darbepoetin
More informationRipamonti C, et al. ASCO 2012 (Abstract 9005)
ZOOM: A Prospective, Randomized Trial of Zoledronic Acid for Long-term Treatment in Patients With Bone-Metastatic Breast Cancer After 1 Year of Standard Zoledronic Acid Treatment D. Amadori, M. Aglietta,
More informationSwami Murugappan MD PhD Hematology Oncology Fellow University of Washington April 27, 2012
Swami Murugappan MD PhD Hematology Oncology Fellow University of Washington April 27, 2012 Outline Clinical indications of recombinant Erythrop0ietin (EPO) Concerns about the use of EPO in chronic kidney
More informationTechnology appraisal guidance Published: 26 November 2014 nice.org.uk/guidance/ta323
Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy Technology appraisal guidance Published: 26 November 2014 nice.org.uk/guidance/ta323
More informationUsing the Hemoglobin Content of Reticulocytes (RET-He) to Evaluate Anemia in Patients With Cancer
Using the Hemoglobin Content of Reticulocytes (RET-He) to Evaluate Anemia in Patients With Cancer Ellinor I. B. Peerschke, PhD, 1,2 Melissa S. Pessin, MD, PhD, 1 and Peter Maslak, MD 1,2 From the 1 Memorial
More informationKey Words. Epoetin alfa Anemia Chemotherapy Iron Cancer
The Oncologist Symptom Management and Supportive Care Intravenous Ferric Gluconate Significantly Improves Response to Epoetin Alfa Versus Oral Iron or No Iron in Anemic Patients with Cancer Receiving Chemotherapy
More informationErythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS *
Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS * DESCRIPTION Erythropoietin is a glycoprotein produced in the kidneys responsible for the stimulation of red blood cell production. Epoetin
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More information